ORIGINAL CONTRIBUTION. Change in Cognitive Function in Older Persons From a Community Population
|
|
- Polly Washington
- 5 years ago
- Views:
Transcription
1 Change in Cognitive Function in Older Persons From a Community Population Relation to Age and Alzheimer Disease ORIGINAL CONTRIBUTION Robert S. Wilson, PhD; Laurel A. Beckett, PhD; David A. Bennett, MD; Marilyn S. Albert, PhD; Denis A. Evans, MD Objective: To examine change in cognitive function in older persons sampled from a community population, and its relation to age and Alzheimer disease. Design: Prospective cohort study with an average of 3.5 years of follow-up. Setting: East Boston, Mass a geographically defined, urban, working-class community. Participants: A stratified, random sample of persons 65 years and older underwent uniform, structured clinical evaluation for Alzheimer disease. The 388 persons (89.2% of those eligible) who completed at least annual follow-up evaluation were studied: 97 had Alzheimer disease at baseline; 95 developed Alzheimer disease during the study; and 96 were unaffected. Outcome Measures: Eight cognitive performance tests were administered, then converted to populationweighted z scores and averaged to create a composite summary measure of cognitive function. Initial level of and change in this score were the outcome measures. Results: In the population as a whole, many persons experienced a decline in cognitive performance, and age was related to both initial level and rate of decline. Analyses were conducted in 3 subgroups: persons with Alzheimer disease at baseline, those who developed Alzheimer disease during the study, and those who remained unaffected. In both Alzheimer disease subgroups, substantial cognitive decline was observed, but neither initial level nor rate of decline was related to age. In unaffected persons, little cognitive decline was evident, and there was a small, inverse association of age with initial level of cognitive function. Conclusion: In a general population sample, there was little evidence of cognitive decline during a 3.5- year period among persons who remained free of Alzheimer disease. Arch Neurol. 999;56: From the Rush Alzheimer s Disease Center and Rush Institute for Healthy Aging (Drs Wilson, Beckett, Bennett, and Evans) and Departments of Neurological Science (Drs Wilson, Bennett, and Evans), Medicine (Drs Beckett and Evans), and Psychology (Dr Wilson), Rush University and Rush-Presbyterian-Saint Luke s Medical Center, Chicago, Ill; and the Departments of Psychiatry and Neurology (Dr Albert), Massachusetts General Hospital and Harvard Medical School, Boston. IN LONGITUDINAL, populationbased studies of persons 65 years and older, advancing age is associated with more rapid cognitive decline,2 and with increased prevalence and incidence of Alzheimer disease. 3-9 It is likely that some of the cognitive decline observed in aged populations reflects Alzheimer disease. Unfortunately, few longitudinal, populationbased studies include clinical evaluation for dementia and Alzheimer disease. Knowledge of the relations among cognitive function, age, and Alzheimer disease comes mainly from studies of persons who are evaluated in clinical settings, -5 but these studies are subject to bias for several reasons. First, a minority of all persons with Alzheimer disease come to medical attention. 6 Therefore, clinical settings are unlikely to represent the full spectrum of Alzheimer disease in the general population. Second, many factors influence who seeks medical attention; in general, persons evaluated in clinical settings are more likely to be male, younger, and have more years of formal education than those with Alzheimer disease in the general population. 6 Third, it is difficult to identify comparable persons without Alzheimer disease in clinical studies. Furthermore, follow-up participation in published longitudinal studies is often low or cannot be determined; this may lead to bias because persons who return for follow-up evaluation may differ from those who do not. In the present study, a stratified random sample of persons from a defined community population underwent uniform structured evaluations that included clinical classification for Alzheimer disease and cognitive function testing. Evaluations were repeated annually for an 274
2 METHODS OVERVIEW OF STUDY DESIGN From January 982 to December 983, the urban community of East Boston, Mass, was censused, and all persons 65 years and older were asked to participate in an interview that included brief tests of memory and cognition. Of those eligible, 8.7% (362/4485) were interviewed and had cognition tested. A random sample of 74 persons, stratified by age, sex, and level of memory performance, was identified for detailed clinical evaluation. Of these 74 persons, 54 died before being asked to participate, 467 (7.8% of survivors) underwent clinical evaluation, and 93 declined participation. Further details of the study design and sampling plan are published elsewhere. 7 BASELINE EVALUATION Diagnostic Classification Structured clinical evaluation of the 467 persons took place an average of 6.3 months after the population interview. Evaluation included a medical history, neurologic examination, cognitive testing, brief psychiatric evaluation, informant interview, laboratory evaluation, and computed tomography of the brain in a subset. Diagnosis of Alzheimer disease was based on National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer s Disease and Related Disorders Association (NINCDS/ ADRDA) 8 criteria, which require a history of cognitive decline and evidence of impaired memory and cognition on examination. Other neurologic and psychiatric conditions judged to contribute to cognitive impairment were also recorded. Cognitive Function Testing Eight tests (Table ) were administered to help inform clinical classification and provide a baseline for measuring change: immediate and delayed recall of a brief story; a spatial working memory task requiring identification of successive additions to a previously viewed stimulus array; naming 5 pictured and 5 actual objects; reading 2 brief phrases; copying simple designs; discriminating geometric figures in a match-to-sample format; and identifying similarities and differences among sets of visually presented stimuli. Additional psychometric information on these tests is reported elsewhere. 7,9,2 FOLLOW-UP CLINICAL EVALUATIONS Follow-up evaluations identical to baseline in essential details took place at annual intervals. Examiners were blinded to data from previous evaluations. DATA ANALYSIS Because of the stratified, random sampling plan, all analyses were weighted back to the population. A summary measure of cognitive function was used in analyses, rather than individual test scores, to minimize floor and ceiling effects and other sources of measurement error. This was especially important because of the longitudinal design of the study and wide range of cognitive ability in populationbased samples of older persons. The summary measure was constructed by converting the raw scores from each of the 8 tests to z scores, using population estimates of the mean and SD. These z scores were averaged to yield the summary score, which was missing if fewer than 4 valid test scores were available. An alternative measure, the total number of correct items on the 8 tests, was used in secondary analyses. Weighted repeated-measures regression models with random-effects error structure were used to describe personspecific paths of cognitive decline and to test the effects of covariates on the initial level of cognitive function and rate of change. 2 The age term was centered at 8 years, near the baseline mean. The primary model included an estimate of the mean overall level of the summary score at the reference age of 8 years. In addition, the model estimated the average difference for each year older or younger at baseline, the average decline per year during follow-up, and a term to test whether the rate of decline during follow-up was related to age at baseline. This model assumed that each person s individual path of cognitive decline followed the estimated mean path, except for random effects that modified the overall level to be higher or lower and the rate of change to be faster or slower. Both random effects were assumed to follow a bivariate normal distribution. The observed measurements were assumed to differ from the person s true path only by independent, identically distributed errors at each time of observation. The SE estimates for the weighted regression coefficients were generated using bootstrap resampling techniques with 2 bootstrap replications, each generating a stratified random sample with replacement from the 388 with less observation per stratum, and recalculating the pseudo maximum likelihood estimates at each replication. 22 average of 3.5 years, with 89.2% of survivors completing at least follow-up evaluation. In analyses weighted to the population, we examined initial level of and change in cognitive function, and their relation to age, in all persons, those with Alzheimer disease at baseline, those who developed Alzheimer disease during the study, and those unaffected. RESULTS Of the 467 persons who completed the baseline clinical evaluation, 32 died before the first follow-up evaluation and 388 completed at least follow-up evaluation from which a summary cognitive score could be computed. Analyses were based on these 388 persons (89.2% of those eligible) who completed an average of 4.5 examinations (range, 2-6), 93.% of those scheduled, during an average interval of 3.5 years. At baseline evaluation, 97 persons met NINCDS/ ADRDA criteria for Alzheimer disease. Because the stratified sampling plan oversampled people with cognitive impairment, a substantial proportion developed Alzheimer disease during follow-up; 95 persons who did not meet criteria for Alzheimer disease at baseline did so on or 275
3 Table. Descriptive Information on Cognitive Function Tests Test Function Assessed Performance Measure Range Immediate story Memory Ideas recalled -6 recall Delayed story recall Memory Ideas recalled -6 Spatial memory test Memory Stimuli identified -7 Naming Language Pictures, objects, -2 named Reading Language Phrases read -2 Copying Perception Design features copied - Matching Perception Design pairs matched -5 Abstraction Perception Similarities, differences identified - Table 3. Change in the Summary Measure of Cognitive Function Among a Random Sample of a Community Population 65 Years or Older* Summary Measure of Cognitive Function Coefficient SE P Annual change during study Age at baseline, y.5.5. Interaction between baseline age and annual change.4.. *Values are from a random-effects regression model and are weighted to reflect sampling probabilities. Table 2. Descriptive Information for 3 Diagnostic Subgroups of a Random Sample of a Community Population 65 Years or Older* Alzheimer Disease at Baseline Population Subgroup Met Criteria for Alzheimer Disease During Follow-up Unaffected Age at baseline, y 82.4 (6.5) 8.2 (6.5) 73.6 (4.7) Proportion female Education, y 5.7 (4.) 6.4 (4.) 9.6 (2.6) Baseline summary cognitive score.57 (.67).487 (.54).267 (.398) Summary Cognitive Score Age, y *All values are weighted to reflect sampling probabilities. Numbers in parentheses are SDs. Cognitive scores are in SD units. Figure. Change in summary cognitive score for each person in population sample. Organized by age at examination; length of each line reflects number of years of observation for that person. more follow-up examinations (4, 24, 3, 5, and 3 on evaluations 2-6, respectively). The remaining 96 persons never met the diagnostic criteria. Table 2 provides descriptive information on the subgroups, weighted to the community population. In comparison to unaffected persons, those with Alzheimer disease were older and less educated, and had lower scores at baseline on the summary measure of cognitive function. Follow-up participation was similar in the subgroups. In an initial analysis of the entire population sample (Table 3), the summary cognitive score declined by an average of.39 standard score units per year (95% confidence interval [CI],.24 to.53). This was compatible with the estimate that the average cognitive score in the entire population was.5 standard score units (95% CI,.39 to.5) lower at baseline for each year of age. On average, cognitive score also declined more rapidly for older persons in the entire population. The estimate of the interaction between baseline age and annual change during the study was.4 (95% CI,.2 to.5) approximately one tenth the size of the term representing annual change, indicating that cognitive score declined approximately % faster for each year older a person was at baseline. Figure shows the estimates of change in cognitive function from this model for each person in the population sample. The slope of each line is a smoothed estimate from all measurements of summary score for that person. Figure is organized according to age of each person at baseline, and the length of each line corresponds to the number of years of observation for that individual. Although the overall trend of cognitive decline with advancing age is evident, there is much heterogeneity; some persons decline sharply, many not at all, and others seem to improve. This variability is not easily accounted for by a simple homogeneous aging process. Moreover, the people who start at lower levels of function appear in Figure to be declining faster; this is confirmed by a significant positive correlation between the person-specific initial levels of cognitive performance and person-specific slopes (r =.36, P.). To examine the contribution of Alzheimer disease to cognitive decline in this community population, analyses were performed for 3 subgroups: persons with Alzheimer disease at baseline, those who developed Alzheimer disease during follow-up, and those who remained unaffected (Table 4). As expected, persons with Alzheimer disease at baseline experienced the largest declines in cognitive function an average summary cognitive score decline of.97 standard score units per year (95% CI,.46 to.47). Average decline among those without Alzheimer disease at baseline but who developed it during the study was somewhat less:.55 standard score units per year (95% CI,.22 to.88). There was no strong effect of age on baseline level of cognitive performance or on rate of decline in performance 276
4 Table 4. Change in the Summary Measure of Cognitive Function Among 3 Diagnostic Subgroups of the Population Sample* Summary Measure of Cognitive Function Coefficient SE P Alzheimer disease at baseline Annual change during study Age at baseline, y.2..7 Interaction between baseline age and annual change Met criteria for Alzheimer disease during follow-up Annual change during study Age at baseline, y.4..7 Interaction between baseline age and annual change Unaffected Annual change during study Age at baseline, y.7.5. Interaction between baseline age and annual change...74 *Values are from random-effects regression models and are weighted to reflect sampling probabilities. Summary Cognitive Score A B for either Alzheimer disease subgroup. The pattern in those who remained free of Alzheimer disease throughout the study was substantially different: their cognitive performance remained stable, with an estimated average annual change of.4 standard score units per year (95% CI,.7 to.25). Baseline level of cognitive function was lower by.7 standard score units (95% CI,.7 to.27) per year of age on average, but there was no evidence that cognitive performance declined more rapidly during the study among older unaffected persons. Figure 2 shows the estimates of change in cognitive performance for persons within diagnostic subgroups. Substantial cognitive decline is evident in persons with Alzheimer disease diagnosed at baseline (Figure 2, A) or during follow-up (Figure 2, B). On average, the rate of decline appears more rapid in the former than in the latter subgroup, although much variability among persons is seen in both. In contrast, little cognitive decline is evident in the unaffected subgroup (Figure 2, C). Within each subgroup, age appears unrelated to change in cognitive function. Secondary analyses addressed 3 potentially confounding factors. First, because level of education is related to age and cognitive test performance and differed in persons with and without Alzheimer disease, analyses were repeated with terms for education and its interaction with years elapsed during the study. Second, other neurologic and psychiatric conditions judged to impair cognition were noted on baseline and follow-up evaluations; these conditions were depression (n = 23), stroke (n = 4), alcoholism (n = 6), Parkinson disease (n = 5), psychosis (n = 5), retardation (n = 2), and subacute combined degeneration (n = 2). Analyses were repeated with these 57 persons excluded. Third, to see if Age, y Figure 2. Change in summary cognitive score by age for each person in population sample diagnosed as having Alzheimer disease at baseline (A), who first met criteria for Alzheimer disease during follow-up (B), or who remained unaffected (C). Organized by age at examination; length of each line reflects number of years of observation for that person. results depended on how the summary measure was formed, analyses were also repeated using the total items correct on the 8 tests instead of the z score measure. Results from these secondary analyses (data not shown) were consistent with those from primary analyses: in the entire population sample, decline occurred and was related to age; in those with Alzheimer disease, decline occurred but was unrelated to age; and in those unaffected, decline did not occur. COMMENT Overall, this community population experienced a measurable decline in cognitive performance during 3.5 years. Dividing the population into diagnostic subgroups, however, demonstrated that substantial cognitive decline was almost completely restricted to persons either who had C 277
5 Alzheimer disease diagnosed at the baseline evaluation or who met criteria for the disease during follow-up. During this period, there was little evidence of cognitive decline with advancing age among persons who remained unaffected by the disease. Occurence of cognitive decline among older persons is well documented, with recent longitudinal, population-based studies providing the most direct evidence.,2 There are few longitudinal studies, however, of the change in cognitive performance among persons who have undergone clinical evaluation and been found to be without dementia or Alzheimer disease. The results of several case-control studies -5 and one populationbased study 23 suggest there is little to no cognitive decline in persons without clinical evidence of dementia or Alzheimer disease during study intervals ranging from about to 5 years. Study data are also relevant to characterizing the course of Alzheimer disease in the general population. Persons diagnosed as having Alzheimer disease at baseline began the study with a summary cognitive score more than one standard score unit below unaffected persons and declined an average of about one tenth of a unit per year. Persons who developed the disease during follow-up began the study with an average cognitive score of about one half of a standard score unit below that of unaffected persons, and declined an average of about one twentieth of a unit annually. The evidence of substantial cognitive impairment in this subgroup at baseline before a clinical diagnosis of Alzheimer disease was made reinforces the view that gradual cognitive decline typically precedes the onset of clinically manifest dementia in this disease. That the rate of cognitive decline was more rapid in persons with baseline Alzheimer disease compared with this group suggests a gradually accelerating rate of decline during the disease course. The relation of age to cognitive decline among persons with Alzheimer disease has not been examined in longitudinal, population-based studies, and studies of clinical samples yielded mixed results. Younger age was associated with more rapid cognitive decline in some studies, but others found the opposite association, 27 mixed results, 28,29 or no association. 3,3-37 Among persons with Alzheimer disease in this population, age was unrelated to change in cognitive function and only marginally related to initial level. It should be emphasized that persons younger than 65 years in this population were not sampled by this study, and questions regarding Alzheimer disease before this age were not addressed. Several methodologic features of this study increase the likelihood that the results are valid. First, participants represented a random sample of persons with and without Alzheimer disease from a geographically defined community population. All persons 65 years and older within the community were eligible, and rates of participation were high, reducing the likelihood of bias from nonrandom initial participation. Second, the rate of participation in the follow-up evaluation was high, and similar for affected and unaffected persons, reducing the likelihood of bias from nonrandom follow-up participation. Third, cognitive function was expressed as a composite of 8 individual performance tests of varying difficulty levels. Use of a composite measure extends the range within which individual differences can be detected, thereby reducing bias from floor or ceiling effects encountered in previous studies. Fourth, high follow-up participation, with an average of 4.5 evenly spaced data collection points and a cognitive measure with minimal floor and ceiling effects, permitted the use of statistical models to characterize person-specific paths of change in cognitive function. This reduced the likelihood of bias from regression to the mean and from inadequate ability to describe within-person correlations. Our study has important limitations. Implementation criteria for the clinical diagnosis of Alzheimer disease can vary among studies because disease onset is typically by minute degrees over a period of time, and different investigators using the same criteria can place the cut point between normality and disease at different places along this continuum. The approach taken in this study use of uniform structured evaluation, prior specification of diagnostic criteria, and blinding of evaluators at each annual evaluation to previous data reduces both individual variation within the study and bias in applying these criteria. Nonetheless, the degree to which substantial cognitive decline is largely restricted to persons who had Alzheimer disease at baseline and to those who developed the disease during the study will depend on the placement of the diagnostic cut point between normality and Alzheimer disease. If criteria that restricted the diagnosis of Alzheimer disease to persons with more severe disease had been used, it is likely that this finding would not have been as strong. Because participants were followed closely with annual clinical evaluations, the study was especially efficient in detecting persons who met the criteria for a diagnosis of Alzheimer disease during follow-up. It is likely that longitudinal clinicopathologic studies will provide the most direct evidence of the contribution of Alzheimer disease to age-related cognitive decline. Our finding of little or no cognitive decline among older persons who are free of Alzheimer disease is consistent with those of the few previous studies that have used diagnostic criteria to distinguish a group free of the disease. Different results might have been obtained with specific (or different global) measures of cognitive function, or with a longer observation period. The results, however, argue against the existence of substantial cognitive decline that would be evident during a period of a few years from advancing age alone. Accepted for publication November 9, 998. This study was supported by contracts (N-AG-- 27 and N-AG--26) and grants (AG5362, AG6789, AG6, and AG963) from the National Institute on Aging, Bethesda, Md. We thank the staff of the East Boston Neighborhood Health Center for their cooperation and support and Charles Owen, MA, for statistical programming. Reprints: Robert S. Wilson, PhD, Rush Institute for Healthy Aging, 645 W Jackson Blvd, Suite 675, Chicago, IL
6 REFERENCES. Evans D, Beckett L, Albert M, et al. Level of education and change in cognitive function in a community population of older persons. Ann Epidemiol. 993;3: Colsher P, Wallace R. Longitudinal application of cognitive function measures in a defined population of community-dwelling elders. Ann Epidemiol. 99;: Bachman D, Wolf P, Linn R, et al. Incidence of dementia and probable Alzheimer s disease in a general population: The Framingham Study. Neurology. 993; 43: Evans D, Scherr P, Cook N, et al. Estimated prevalence of Alzheimer s disease in the United States. Milbank Q. 99;68: Fratiglioni L, Viitanen M, von Strauss E, Tontodonati V, Herlitz A, Winblad B. Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the Kungsholmen project, Stockholm. Neurology. 997;48: Hebert L, Scherr P, Beckett L, et al. Age-specific incidence of Alzheimer s disease in a community population. JAMA. 995;43: Ott A, Breteler M, van Harskamp F, et al. Prevalence of Alzheimer s disease and vascular dementia: association with education: the Rotterdam Study. BMJ. 995; 3: WhiteL,PetrovitchH,RossG,etal.PrevalenceofdementiainolderJapanese-American men in Hawaii: the Honolulu-Asia aging study. JAMA. 996;276: Zhang M, Katzman R, Salmon D, et al. The prevalence of dementia and Alzheimer s disease in Shanghai, China: impact of age, gender, and education. Ann Neurol. 99;27: Botwinick J, Storandt M, Berg L. A longitudinal, behavioral study of senile dementia of the Alzheimer type. Arch Neurol. 986;43: Fromm D, Holland A, Nebes R, Oakley M. A longitudinal study of word-reading ability in Alzheimer's disease: evidence from the National Adult Reading Test. Cortex. 99;27: Rebok G, Brandt J, Folstein M. Longitudinal cognitive decline in patients with Alzheimer's disease. J Geriatr Psychiatry Neurol. 99;3: Stern R, Mohs R, Davidson M, et al. A longitudinal study of Alzheimer s disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry. 994;5: Ripich D, Petrill S, Whitehouse P, Ziol E. Gender differences in language of AD patients: a longitudinal study. Neurology. 995;45: Kaszniak A, Wilson R, Fox J, Stebbins G. Cognitive assessment in Alzheimer s disease: cross-sectional and longitudinal perspectives. Can J Neurol Sci. 986; 3: Ross G, Abbott R, Petrovitch H, et al. Frequency and characteristics of silent dementia among elderly Japanese-American men. JAMA. 997;277: Evans D, Funkenstein H, Albert M, et al. Prevalence of Alzheimer s disease in a community population of older persons: higher than previously reported. JAMA. 989;262: McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer s Disease. Neurology. 984;34: Albert M, Smith L, Scherr P, et al. Use of brief cognitive tests to identify individuals in the community with clinically-diagnosed Alzheimer s disease. Int J Neurosci. 99;57: Evans D, Scherr P, Cook N, et al. Assessing change in cognitive function in community populations of older adults. In: Proceedings of the 987 Public Health Conference on Records and Statistics. Hyattsville, Md: US Dept of Health and Human Services;987: Laird N, Ware J. Random-effects models for longitudinal data. Biometrics. 982; 38: Efron B, Tibshirani R. Discussion and further topics. In: An Introduction to the Bootstrap. New York, NY: Chapman & Hall; 993: Jacqmin-Gadda H, Gabrigoule C, Commenges D, Dartigues J. A 5-year longitudinal study of the Mini-Mental State Examination normal aging. Am J Epidemiol. 997;45: Jacobs D, Sano M, Marder K, et al. Age at onset of Alzheimer s disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology. 994;44: Lucca U, Comelli M, Tettamanti M, Triaboschi P, Spagnoli A. Rate of progression and prognostic factors in Alzheimer's disease: a prospective study. J Am Geriatr Soc. 993;4: Mortimer J, Ebbitt B, Jun S-P, Finch M. Predictors of cognitive and functional progression in patients with probable Alzheimer s disease. Neurology. 992;42: Huff F, Growdon J, Corkin S, Rosen T. Age at onset and rate of progression of Alzheimer s disease. J Am Geriatr Soc. 987;35: Ortof E, Crystal H. Rate of progression of Alzheimer s disease. J Am Geriatr Soc. 989;37: Teri L, McCurry S, Edland S, Kukull W, Larson E. Cognitive decline in Alzheimer s disease: a longitudinal investigation of risk factors for accelerated decline [abstract]. J Gerontol Med Sci. 995;5:M49-M Boller F, Becker J, Holland A, et al. Predictors of decline in Alzheimer s disease. Cortex. 99;27: Burns A, Jacoby R, Levy R. Progression of cognitive impairment in Alzheimer s disease. J Am Geriatr Soc. 99;39: Frisoni G, Govoni S, Geroldi C, et al. Gene dose of the e4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer s disease. Ann Neurol. 995;37: Haupt M, Pollmann S, Kurz A. Symptom progression in Alzheimer s disease: relation to onset age and familial aggregation. Acta Neurol Scand. 993;88: Katzman R, Brown T, Thal L, et al. Comparison of rate of annual change of mental status score in four independent studies of patients with Alzheimer s disease. Ann Neurol. 988;24: Stern R, Mohs R, Bierer L, et al. Deterioration on the blessed test in Alzheimer s disease: longitudinal data and their implications for clinical trials and identification of subtypes. Psychiatry Res. 992;42: Teri L, Hughes J, Larson E. Cognitive deterioration in Alzheimer s disease: behavioral and health factors. J Gerontol. 99;45: Wolfe N, Reed B, Eberling J, Jagust W. Temporal lobe perfusion on single photon emission computed tomography predicts the rate of cognitive decline in Alzheimer s disease. Arch Neurol. 995;52:
Hallucinations, delusions, and cognitive decline in Alzheimer s disease
172 Department of Neurological Sciences, Rush Alzheimer s Disease Center and Rush Institute for Healthy Aging, 1645 West Jackson Boulevard, Suite 675, Chicago, Illinois 60612, USA R S Wilson D W Gilley
More informationApplication of a Growth Curve Approach to Modeling the Progression of Alzheimer's Disease
Journal of Gerontology: MEDICAL SCIENCES 1996. Vol. 51 A. No. 4. M179-MI84 Copyright 1996 by The Ceromological Society of America Application of a Growth Curve Approach to Modeling the Progression of Alzheimer's
More informationValidity of Family History for the Diagnosis of Dementia Among Siblings of Patients With Late-onset Alzheimer s Disease
Genetic Epidemiology 15:215 223 (1998) Validity of Family History for the Diagnosis of Dementia Among Siblings of Patients With Late-onset Alzheimer s Disease G. Devi, 1,3 * K. Marder, 1,3 P.W. Schofield,
More informationORIGINAL CONTRIBUTION. Longitudinal Assessment of Patient Dependence in Alzheimer Disease
ORIGINAL CONTRIBUTION Longitudinal Assessment of Patient Dependence in Alzheimer Disease Adam M. Brickman, MA; Aliza Riba, BA; Karen Bell, MD; Karen Marder, MD, MPH; Marilyn Albert, PhD; Jason Brandt,
More informationDEMENTIA DUE TO ALZHEImer
ORIGINAL CONTRIBUTION Cognitive Decline in Prodromal Alzheimer Disease and Mild Cognitive Impairment Robert S. Wilson, PhD; Sue E. Leurgans, PhD; Patricia A. Boyle, PhD; David A. Bennett, MD Objective:
More informationAccelerated Memory Decline in Alzheimer s Disease With Apolipoprotein e4 Allele
Accelerated Memory Decline in Alzheimer s Disease With Apolipoprotein e4 Allele Nobutsugu Hirono, M.D., Ph.D. Mamoru Hashimoto, M.D., Ph.D. Minoru Yasuda, M.D., Ph.D. Hirokazu Kazui, M.D., Ph.D. Etsuro
More informationORIGINAL CONTRIBUTION. Response of Patients With Alzheimer Disease to Rivastigmine Treatment Is Predicted by the Rate of Disease Progression
ORIGINAL CONTRIBUTION Response of Patients With Alzheimer Disease to Rivastigmine Treatment Is Predicted by the Rate of Disease Progression Martin R. Farlow, MD; Ann Hake, MD; John Messina, PharmD; Richard
More informationLong-term follow-up studies suggest that elevated blood
Decline in Blood Pressure Over Time and Risk of Dementia A Longitudinal Study From the Kungsholmen Project Chengxuan Qiu, MD, PhD; Eva von Strauss, PhD; Bengt Winblad, MD, PhD; Laura Fratiglioni, MD, PhD
More informationNational estimates of the prevalence of Alzheimer s disease in the United States
Alzheimer s & Dementia 7 (2011) 61 73 National estimates of the prevalence of Alzheimer s disease in the United States Ron Brookmeyer a, *, Denis A. Evans b,c, Liesi Hebert b, Kenneth M. Langa d,e,f, Steven
More informationThe effect of aging on cognitive function in a South Indian Population
International Journal of Scientific and Research Publications, Volume 3, Issue 5, May 2013 1 The effect of aging on cognitive function in a South Indian Population Suzanne Maria D cruz *, Navin Rajaratnam
More informationThe Reliability and Validity of the Korean Instrumental Activities of Daily Living (K-IADL)
The Reliability and Validity of the Korean Instrumental Activities of Daily Living (K-IADL Sue J. Kang, M.S., Seong Hye Choi, M.D.*, Byung H. Lee, M.A., Jay C. Kwon, M.D., Duk L. Na, M.D., Seol-Heui Han
More informationORIGINAL CONTRIBUTION. APOE Genotype, Family History of Dementia, and Alzheimer Disease Risk
ORIGINAL CONTRIBUTION APOE Genotype, Family History of Dementia, and Alzheimer Disease Risk A 6-Year Follow-up Study Wenyong Huang, MD; Chengxuan Qiu, MD, PhD; Eva von Strauss, PhD; Bengt Winblad, MD,
More informationRecognition of Alzheimer s Disease: the 7 Minute Screen
265 Recognition of Alzheimer s Disease: the 7 Minute Screen Paul R. Solomon, PhD; William W. Pendlebury, MD Background and Objectives: Because Alzheimer s disease (AD) tends to be underdiagnosed, we developed
More informationAnosognosia, or loss of insight into one s cognitive
REGULAR ARTICLES Anosognosia Is a Significant Predictor of Apathy in Alzheimer s Disease Sergio E. Starkstein, M.D., Ph.D. Simone Brockman, M.A. David Bruce, M.D. Gustavo Petracca, M.D. Anosognosia and
More informationORIGINAL CONTRIBUTION. Comparison of the Short Test of Mental Status and the Mini-Mental State Examination in Mild Cognitive Impairment
ORIGINAL CONTRIBUTION Comparison of the Short Test of Mental Status and the Mini-Mental State Examination in Mild Cognitive Impairment David F. Tang-Wai, MDCM; David S. Knopman, MD; Yonas E. Geda, MD;
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Heart Failure and Risk of Dementia and Alzheimer Disease A Population-Based Cohort Study Chengxuan Qiu, MD, PhD; Bengt Winblad, MD, PhD; Alessandra Marengoni, MD; Inga Klarin, MD;
More informationIncidence of Dementia and Alzheimer Disease in 2 Communities
ORIGINAL CONTRIBUTION Incidence of Dementia and Alzheimer Disease in 2 Communities Residing in Ibadan, Nigeria, and Residing in Indianapolis, Indiana Hugh C. Hendrie, MB, ChB Adesola Ogunniyi, MD Kathleen
More informationThe Cross-sectional Association Between Blood Pressure and Alzheimer s Disease in a Biracial Community Population of Older Persons
Journal of Gerontology: MEDICAL SCIENCES 2000, Vol. 55A, No. 3, M130 M136 Copyright 2000 by The Gerontological Society of America The Cross-sectional Association Between Blood Pressure and Alzheimer s
More informationClinical Study Depressive Symptom Clusters and Neuropsychological Performance in Mild Alzheimer s and Cognitively Normal Elderly
Hindawi Publishing Corporation Depression Research and Treatment Volume 2011, Article ID 396958, 6 pages doi:10.1155/2011/396958 Clinical Study Depressive Symptom Clusters and Neuropsychological Performance
More informationThe Zarit Burden Interview: A New Short Version and Screening Version
The Gerontologist Vol. 41, No. 5, 652 657 Copyright 2001 by The Gerontological Society of America The Zarit Burden Interview: A New Short Version and Screening Version Michel Bédard, PhD, 1,2 D. William
More informationNeuropsychological detection and characterization of preclinical Alzheimer s disease
Neuropsychological detection and characterization of preclinical Alzheimer s disease D.M. Jacobs, PhD; M. Sano, PhD; G. Dooneief, MD; K. Marder, MD; K.L. Bell, MD; and Y. Stern, PhD Article abstract-we
More informationUDS Progress Report. -Standardization and Training Meeting 11/18/05, Chicago. -Data Managers Meeting 1/20/06, Chicago
UDS Progress Report -Standardization and Training Meeting 11/18/05, Chicago -Data Managers Meeting 1/20/06, Chicago -Training material available: Gold standard UDS informant and participant interviews
More informationThe effect of education and occupational complexity on rate of cognitive decline in Alzheimer s patients
Journal of the International Neuropsychological Society (2006), 12, 147 152. Copyright 2006 INS. Published by Cambridge University Press. Printed in the USA. DOI: 10.10170S1355617706060206 BRIEF COMMUNICATION
More informationFour Tissue Segmentation in ADNI II
Four Tissue Segmentation in ADNI II Charles DeCarli, MD, Pauline Maillard, PhD, Evan Fletcher, PhD Department of Neurology and Center for Neuroscience, University of California at Davis Summary Table of
More informationIncidence of Dementia over Three Decades in the Framingham Heart Study
The new england journal of medicine Original Article Incidence of Dementia over Three Decades in the Framingham Heart Study Claudia L. Satizabal, Ph.D., Alexa S. Beiser, Ph.D., Vincent Chouraki, M.D.,
More informationEstimating the Validity of the Korean Version of Expanded Clinical Dementia Rating (CDR) Scale
Estimating the Validity of the Korean Version of Expanded Clinical Dementia Rating (CDR) Scale Seong Hye Choi, M.D.*, Duk L. Na, M.D., Byung Hwa Lee, M.A., Dong-Seog Hahm, M.D., Jee Hyang Jeong, M.D.,
More informationHopkins Verbal Learning Test Revised: Norms for Elderly African Americans
The Clinical Neuropsychologist 1385-4046/02/1603-356$16.00 2002, Vol. 16, No. 3, pp. 356 372 # Swets & Zeitlinger Hopkins Verbal Learning Test Revised: Norms for Elderly African Americans Melissa A. Friedman
More informationDementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology
Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language
More informationNIH Public Access Author Manuscript Metab Brain Dis. Author manuscript; available in PMC 2011 October 24.
NIH Public Access Author Manuscript Published in final edited form as: Metab Brain Dis. 2006 September ; 21(2-3): 235 240. doi:10.1007/s11011-006-9017-2. Risk factors for incident Alzheimer s disease in
More informationMild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
More informationModelling Mini Mental State Examination changes in Alzheimer s disease
STATISTICS IN MEDICINE Statist. Med. 2000; 19:1607 1616 Modelling Mini Mental State Examination changes in Alzheimer s disease Marta S. Mendiondo 1; ;, J. Wesson Ashford 2, Richard J. Kryscio 3 and Frederick
More informationDoes Education Level Determine the Course of Cognitive Decline?
Age and Ageing 1996:25:392-397 Does Education Level Determine the Course of Cognitive Decline? DIDIER LEIBOVICI, KAREN RITCHIE, BERNARD LEDESE, JACQUES TOUCHON Summary Many studies have implicated low
More informationPapers. Smoking and dementia in male British doctors: prospective study. Abstract. Subjects and methods. Introduction
Smoking and dementia in male British doctors: prospective study Richard Doll, Richard Peto, Jillian Boreham, Isabelle Sutherland Abstract Objective To assess the possible association between smoking and
More informationRisk Factors for Vascular Dementia: A Hospital-Based Study in Taiwan
22 Risk Factors for Vascular Dementia: A Hospital-Based Study in Taiwan Jun-Cheng Lin 1,2, Wen-Chuin Hsu 1, Hai-Pei Hsu 1,2, Hon-Chung Fung 1, and Sien-Tsong Chen 1 Abstract- Background: In Taiwan, next
More informationA semantic verbal fluency test for English- and Spanish-speaking older Mexican-Americans
Archives of Clinical Neuropsychology 20 (2005) 199 208 A semantic verbal fluency test for English- and Spanish-speaking older Mexican-Americans Hector M. González a,, Dan Mungas b, Mary N. Haan a a University
More informationChapter 7. Depression and cognitive impairment in old age: what comes first?
Chapter 7 Depression and cognitive impairment in old age: what comes first? Vinkers DJ,Gussekloo J,StekML,W estendorp RGJ,van der Mast RC. Depression and cognitive impairment in old age: what comes first?
More informationCannabis Use and Cognitive Decline in Persons under 65 Years of Age
American Journal of Epidemiology Copyright O 1999 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 149, 9 Printed In U.SA. ORIGINAL CONTRIBUTIONS Cannabis Use
More informationWhy would caregivers not want to treat their relative's Alzheimer's disease?
University of Pennsylvania ScholarlyCommons Neuroethics Publications Center for Neuroscience & Society 10-1-2003 Why would caregivers not want to treat their relative's Alzheimer's disease? Jason Karlawish
More informationCognitive Decline in Patients with Alzheimer's Disease, Vascular Dementia and Senile Dementia of Lewy Body Type
Age and Ageing 1996.25:209-21 3 Cognitive Decline in atients with Alzheimer's Disease, Vascular Dementia and Senile Dementia of Lewy Body Type C. BALLARD, A. ATEL, F. OYEBODE, G. WILCOCK Summary One hundred
More informationS ubjects with mild cognitive impairment (MCI) often
1348 PAPER Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer s disease? P J Visser, P Scheltens, F R J Verhey... See end of article for authors affiliations... Correspondence
More informationPreclinical Symptoms of Major Depression in Very Old Age: A Prospective Longitudinal Study
BERGER, PRECLINICAL Am J Psychiatry SMALL, SYMPTOMS FORSELL, 155:8, August OF ET MAJOR AL. 1998 DEPRESSION Preclinical Symptoms of Major Depression in Very Old Age: A Prospective Longitudinal Study Anna-Karin
More informationSupplementary Online Content
Supplementary Online Content Atri A, Frölich L, Ballard C, et al. Effect of idalopirdine as adjunct to cholinesterase inhibitors on in cognition in patients with Alzheimer disease: three randomized clinical
More informationPredictors of disease course in patients with probable Alzheimer's disease
Article abstract-the presence of extrapyramidal signs or psychosis may indicate greater disability in patients with probable Alzheimer's disease. We evaluated the ability of these signs, noted at a patient's
More informationCognitive Abilities Screening Instrument, Chinese Version 2.0 (CASI C-2.0): Administration and Clinical Application
Continuing Medical Education 180 Cognitive Abilities Screening Instrument, Chinese Version 2.0 (CASI C-2.0): Administration and Clinical Application Ker-Neng Lin 1,2, Pei-Ning Wang 1,3, Hsiu-Chih Liu 1,3,
More informationORIGINAL CONTRIBUTION. Functional Correlates and Prevalence of Mild Parkinsonian Signs in a Community Population of Older People
ORIGINAL CONTRIBUTION Functional Correlates and Prevalence of Mild Parkinsonian Signs in a Community Population of Older People Elan D. Louis, MS, MD; Ming X. Tang, PhD; Nicole Schupf, PhD; Richard Mayeux,
More informationPapers. Detection of Alzheimer s disease and dementia in the preclinical phase: population based cohort study. Abstract.
Detection of Alzheimer s disease and dementia in the preclinical phase: population based cohort study Katie Palmer, Lars Bäckman, Bengt Winblad, Laura Fratiglioni Abstract Objectives To evaluate a simple
More informationORIGINAL CONTRIBUTION. Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease
ORIGINAL CONTRIBUTION Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease Miia Kivipelto, MD, PhD; Tiia Ngandu, BM; Laura Fratiglioni, MD, PhD; Matti Viitanen, MD,
More informationCONNERS K-CPT 2. Conners Kiddie Continuous Performance Test 2 nd Edition C. Keith Conners, Ph.D.
CONNERS K-CPT 2 Conners Kiddie Continuous Performance Test 2 nd Edition C. Keith Conners, Ph.D. Assessment Report Name/ID: Jen Sample / 334 Age: 5 Gender: Female Birth Date: June 30, 2008 Grade: Administration
More informationFunctional assessment scales in detecting dementia
Age and Ageing 1997; 26: 393-400 Functional assessment scales in detecting dementia KATI JUVA, MATTI MAKELA 1, TIMO ERKINJUNTTI, RAIMO SULKAVA 2, RAIJA YUKOSKI, JAAKKO VALVANNE 1, REIJO TILVIS ' Memory
More informationKey Words: Hypertension, Blood pressure, Cognitive impairment, Age 대한신경과학회지 22 권 1 호
Seul-Ki Jeong, M.D., Hae-Sung Nam, M.D., Min-Ho Shin, M.D., Sun-Seok Kweon, M.D., Myong-Ho Son, M.D., Eui-Ju Son, M.D., Jae-Min Kim, M.D., Ki-Hyun Cho, M.D. Background: It has been reported that the association
More informationUnderstanding of Senile Dementia by Children and Adolescents: Why Grandma Can t Remember Me?
138 Understanding of Senile Dementia by Children and Adolescents: Why Grandma Can t Remember Me? Jong-Ling Fuh 1, Shuu-Jiun Wang 1, and Kai-Di Juang 2 Abstract- Background: The present study sought to
More informationLongitudinal Study of Quality of Life in People with Advanced Alzheimer s Disease
Longitudinal Study of Quality of Life in People with Advanced Alzheimer s Disease Steven M. Albert, Ph.D., M.Sc., Diane M. Jacobs, Ph.D. Mary Sano, Ph.D., Karen Marder, M.D. Karen Bell, M.D., Davangere
More informationMini-Mental State Examination Item Scores as Predictors of Alzheimer's Disease: Incidence Data From the Kungsholmen Project, Stockholm
Journal of Gerontology: MEDICAL SCIENCES 1997, Vol. 52A. No. 5, M299-M304 Copyright 1997 by The Gemntological Society of America Mini-Mental State Examination Item Scores as Predictors of Alzheimer's Disease:
More informationTreatment of AD with Stabilized Oral NADH: Preliminary Findings
MS # 200 000 128 Treatment of AD with Stabilized Oral NADH: Preliminary Findings G.G. Kay, PhD, V. N. Starbuck, PhD and S. L. Cohan, MD, PhD Department of Neurology, Georgetown University School of Medicine
More informationThe prevalence of dementia in the People s Republic of China: a systematic analysis of studies
Age and Ageing 2007; 36: 619 624 The Author 2007. Published by Oxford University Press on behalf of the British Geriatrics Society. doi:10.1093/ageing/afm128 All rights reserved. For Permissions, please
More informationThe 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study
doi:10.103/brain/awh41 Brain (200), 12, 103 1101 The year cognitive decline before dementia of the Alzheimer type: a prospective population-based study Hélène Amieva, 1 Hélène Jacqmin-Gadda, 2 Jean-Marc
More informationChapter 4. Cognitive decline precedes late-life longitudinal changes in vascular risk factors
Cognitive decline precedes late-life longitudinal changes in vascular risk factors P. van Vliet, R.G.J. Westendorp, D. van Heemst, A.J.M. de Craen, A.M. Oleksik J Neurol Neurosurg Psychiatry 2010;81:1028-1032
More informationSIGNS of parkinsonism 1-3 are frequently found on neurologic
Vol. 334 No. 2 PARKINSONIAN SIGNS AND ASSOCIATED MORTALITY IN OLDER PEOPLE 71 PREVALENCE OF PARKINSONIAN SIGNS AND ASSOCIATED MORTALITY IN A COMMUNITY POPULATION OF OLDER PEOPLE DAVID A. BENNETT, M.D.,
More informationExamining the influence of gender, education, social class and birth cohort on MMSE tracking over time: a population-based prospective cohort study
Matthews et al. BMC Geriatrics 2012, 12:45 RESEARCH ARTICLE Open Access Examining the influence of gender, education, social class and birth cohort on MMSE tracking over time: a population-based prospective
More informationSUPPLEMENTARY APPENDIX
Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 23 million people and more than 100,000 cases of dementia SUPPLEMENTARY APPENDIX Supplementary Methods Newcastle
More informationTHE ROLE OF ACTIVITIES OF DAILY LIVING IN THE MCI SYNDROME
PERNECZKY 15/06/06 14:35 Page 1 THE ROLE OF ACTIVITIES OF DAILY LIVING IN THE MCI SYNDROME R. PERNECZKY, A. KURZ Department of Psychiatry and Psychotherapy, Technical University of Munich, Germany. Correspondence
More informationPopulations for Epidemiologic Study of the Elderly
Journal of Gerontology: MEDICAL SCIENCES 2002, Vol. 57A, No. 10, M678 M682 Copyright 2002 by The Gerontological Society of America The Interaction of Cognitive and Emotional Status on Subsequent Physical
More informationIncidence and Risk of Dementia
American Journal of Epidemiology Copyright O 1998 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 147, No. 6 Printed In USA. Incidence and Risk of Dementia
More informationK. Kahle-Wrobleski 1, J.S. Andrews 1, M. Belger 2, S. Gauthier 3, Y. Stern 4, D.M. Rentz 5, D. Galasko 6
The Journal of Prevention of Alzheimer s Disease - JPAD Volume 2, Number 2, 2015 Clinical and Economic Characteristics of Milestones along the Continuum of Alzheimer s Disease: Transforming Functional
More informationORIGINAL CONTRIBUTION. Dementia and Alzheimer Disease Incidence
Dementia and Alzheimer Disease Incidence A Prospective Cohort Study ORIGINAL CONTRIBUTION Walter A. Kukull, PhD; Roger Higdon, PhD; James D. Bowen, MD; Wayne C. McCormick, MD; Linda Teri, PhD; Gerard D.
More informationORIGINAL CONTRIBUTION. Detecting Dementia With the Mini-Mental State Examination in Highly Educated Individuals
ORIGINAL CONTRIBUTION Detecting Dementia With the Mini-Mental State Examination in Highly Educated Individuals Sid E. O Bryant, PhD; Joy D. Humphreys, MA; Glenn E. Smith, PhD; Robert J. Ivnik, PhD; Neill
More informationAlzheimer disease is one of the leading causes of death. Article
Annals of Internal Medicine Article Survival after Initial Diagnosis of Alzheimer Disease Eric B. Larson, MD, MPH; Marie-Florence Shadlen, MD; Li Wang, MS; Wayne C. McCormick, MD, MPH; James D. Bowen,
More informationLeisure Activities and the Risk of Dementia in the Elderly
The new england journal of medicine original article Leisure Activities and the Risk of Dementia in the Elderly Joe Verghese, M.D., Richard B. Lipton, M.D., Mindy J. Katz, M.P.H., Charles B. Hall, Ph.D.,
More information/ffl. Cohort Study of Vitamin C Intake and Cognitive Impairment
/ffl American Journal of Epidemiology Copyright 1998 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 148, No. 1 Printed in U.S.A. A BRIEF ORIGINAL CONTRIBUTION
More informationChapter 1. Introduction
The older people get, the bigger the chance of losing cognitive abilities and ultimately to develop dementia. Increasing age is the largest known risk factor of dementia, with a prevalence of 1% in people
More informationRelation of Education and Occupation-based Socioeconomic Status to Incident Alzheimer s Disease
American Journal of Epidemiology Copyright 2004 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 159, No. 2 Printed in U.S.A. DOI: 10.1093/aje/kwh018 Relation of Education
More informationAlzheimer s Disease. Clinical characteristics of late-onset Alzheimer s disease (LOAD) A/Prof David Darby
Alzheimer s Disease Clinical characteristics of late-onset Alzheimer s disease (LOAD) A/Prof David Darby Florey Institute of Neuroscience and Mental Health 28-6-2013 The burden of late-onset Alzheimer
More informationNIH Public Access Author Manuscript J Int Neuropsychol Soc. Author manuscript; available in PMC 2010 August 12.
NIH Public Access Author Manuscript Published in final edited form as: J Int Neuropsychol Soc. 2010 July ; 16(4): 651 660. doi:10.1017/s1355617710000421. Predicting cognitive decline and conversion to
More informationALZHEIMER DISEASE (AD)
ORIGINAL INVESTIGATION Performance-Based Physical Function and Future Dementia in Older People Li Wang, MS; Eric B. Larson, MD, MPH; James D. Bowen, MD; Gerald van Belle, PhD Background: The association
More informationPhysical Activity, Physical Function, and Incident Dementia in Elderly Men: The Honolulu Asia Aging Study
Journal of Gerontology: MEDICAL SCIENCES 2008, Vol. 63A, No. 5, 529 535 Copyright 2008 by The Gerontological Society of America Physical Activity, Physical Function, and Incident Dementia in Elderly Men:
More informationORIGINAL CONTRIBUTION. Dietary Folate and Vitamin B 12 Intake and Cognitive Decline Among Community-Dwelling Older Persons
ORIGINAL CONTRIBUTION Dietary Folate and Vitamin B 12 Intake and Cognitive Decline Among Community-Dwelling Older Persons Martha Clare Morris, ScD; Denis A. Evans, MD; Julia L. Bienias, ScD; Christine
More informationThe Long-term Prognosis of Delirium
The Long-term Prognosis of Jane McCusker, MD, DrPH, Professor, Epidemiology and Biostatistics, McGill University; Head, Clinical Epidemiology and Community Studies, St. Mary s Hospital, Montreal, QC. Nine
More informationCognitive Reserve and the Relationship Between Depressive Symptoms and Awareness of Deficits in Dementia
Cognitive Reserve and the Relationship Between Depressive Symptoms and Awareness of Deficits in Dementia Mary Beth Spitznagel, Ph.D. Geoffrey Tremont, Ph.D. Laura B. Brown, Ph.D. John Gunstad, Ph.D. Depression
More informationCHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE
CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE 5.1 GENERAL BACKGROUND Neuropsychological assessment plays a crucial role in the assessment of cognitive decline in older age. In India, there
More informationAspirin Use and Cognitive Function in the Elderly
American Journal of Epidemiology Copyright O 1996 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 143, No. 7 Printed In U.S-A. Aspirin Use and Cognitive Function
More informationMetabolic syndrome is a constellation of cardiovascular
and Cognitive Decline in Elderly Latinos: Findings from the Sacramento Area Latino Study of Aging Study Kristine Yaffe, MD, wzk Mary Haan, DrPH, MPH, z Terri Blackwell, MA, # Elena Cherkasova, BA, Rachel
More informationORIGINAL CONTRIBUTION. Diagnostic Validity of the Dementia Questionnaire for Alzheimer Disease
ORIGINAL CONTRIBUTION Diagnostic Validity of the Dementia Questionnaire for Alzheimer Disease Ronald J. Ellis, MD, PhD; Kaining Jan, MD; Claudia Kawas, MD; William C. Koller, MD; Kelly E. Lyons, PhD; Dilip
More informationThe course of neuropsychiatric symptoms in dementia. Part II: relationships among behavioural sub-syndromes and the influence of clinical variables
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Int J Geriatr Psychiatry 2005; 20: 531 536. Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/gps.1317 The course of neuropsychiatric
More informationDiversity and Dementia
Diversity and Dementia Kala M. Mehta, DSc, MPH January 17, 2012 Overview Background Incidence and Prevalence of Dementia Why are these differences found? What s important for diverse dementia patients
More informationPREVALENCE AND CORRELATES OF ANXIETY IN ALZHEIMER S DISEASE
166 Chemerinski et al. DEPRESSION AND ANXIETY 7:166 170 (1998) PREVALENCE AND CORRELATES OF ANXIETY IN ALZHEIMER S DISEASE Erán Chemerinski, M.D., 1 * Gustavo Petracca, M.D., 1 Facundo Manes, M.D., 2 Ramón
More informationBlood Pressure and Performance on the Mini-Mental State Examination in the Very Old
American Journal of Epidemiology Copyright 1997 by The Johns Hopkins University School of Hygiene and ublic Health All rights reserved Vol. 145,. 12 rinted In USA. Blood ressure and erformance on the Mini-Mental
More informationC holinomimetic drugs constitute the first line of treatment
310 PAPER Cholinesterase inhibitor treatment alters the natural history of Alzheimer s disease O L Lopez, J T Becker, S Wisniewski, J Saxton, D I Kaufer, S T DeKosky... See end of article for authors affiliations...
More informationRisk Factors for Alzheimer s Disease: A Prospective Analysis from the Canadian Study of Health and Aging
American Journal of Epidemiology Copyright 2002 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 156, No. 5 Printed in U.S.A. DOI: 10.1093/aje/kwf074 Risk Factors for Alzheimer
More informationAdverse Outcomes After Hospitalization and Delirium in Persons With Alzheimer Disease
Adverse Outcomes After Hospitalization and Delirium in Persons With Alzheimer Disease J. Sukanya 05.Jul.2012 Outline Background Methods Results Discussion Appraisal Background Common outcomes in hospitalized
More informationProceedings of the Annual Meeting of the American Statistical Association, August 5-9, 2001
Proceedings of the Annual Meeting of the American Statistical Association, August 5-9, 1 SCREENING FOR DEMENTIA USING LONGITUDINAL MEASUREMENTS OF COGNITION Christopher H. Morrell, Mathematical Sciences
More informationPhysostigmme in Alzheimer s Disease
Effects of Oral Physostigmme in Alzheimer s Disease Yaakov Stern, PhD,? Mary Sano, PhD,* and hchard Mayeux, MD t Previous studies of oral physostigmine in the treatment of Alzheimer s disease have: (1)
More information.. Mini-Mental State Examination MMSE TPQ
Cloninger Tridimensional Personality Questionnaire TPQ Cloninger.... Mini-Mental State Examination MMSE Tridimensional Personality Questionnaire TPQ : U=., p
More informationBehavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients
Blackwell Science, LtdOxford, UKPCNPsychiatry and Clinical Neurosciences1323-13162005 Blackwell Publishing Pty Ltd593274279Original ArticleDementia and mild AlzheimersJ. Shimabukuro et al. Psychiatry and
More informationORIGINAL CONTRIBUTION. An Investigation of Clinical Correlates of Lewy Bodies in Autopsy-Proven Alzheimer Disease
ORIGINAL CONTRIBUTION An Investigation of Clinical Correlates of Lewy Bodies in Autopsy-Proven Alzheimer Disease Yaakov Stern, PhD; Diane Jacobs, PhD; James Goldman, MD; Estrella Gomez-Tortosa, PhD; Bradley
More informationCentral auditory function in early Alzheimer s disease and in mild cognitive impairment
Age and Ageing Advance Access published January 13, 2011 Age and Ageing 2011; 0: 1 5 doi: 10.1093/ageing/afq168 The Author 2011. Published by Oxford University Press on behalf of the British Geriatrics
More informationEPIDEMIOLOGY AND RISK FACTORS OF DEMENTIA
v2 EPIDEMIOLOGY AND RISK FACTORS OF DEMENTIA See end of article for authors affiliations Correspondence to: W M van der Flier, Department of Neurology and Alzheimer Center, Vrije Universiteit Medical Center,
More informationORIGINAL CONTRIBUTION. History of Vascular Disease and Mild Parkinsonian Signs in Community-Dwelling Elderly Individuals
ORIGINAL CONTRIBUTION History of Vascular Disease and Mild Parkinsonian Signs in Community-Dwelling Elderly Individuals Elan D. Louis, MD, MS; Jose A. Luchsinger, MD, MPH Background: Mild parkinsonian
More informationMicroinfarct Pathology, Dementia, and Cognitive Systems
Microinfarct Pathology, Dementia, and Cognitive Systems Zoe Arvanitakis, MD, MS; Sue E. Leurgans, PhD; Lisa L. Barnes, PhD; David A. Bennett, MD; Julie A. Schneider, MD, MS Background and Purpose Little
More information